IP Library Granted Patent US 8,131,371
Granted Patent B2
US 8,131,371 · App. 11/403,329 · Granted Mar 6, 2012

Methods and apparatus for monopolar renal neuromodulation

Assignee: Ardian, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,131,371
App. No.
11/403,329
Granted
Mar 6, 2012
Kind
B2
Abstract

Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.

Claims (33)

1. A method for treating diagnosed hypertension by renal neuromodulation of a human patient, the method comprising:

placing a monopolar electrode in proximity to a post-ganglionic nerve that innervates a kidney of the patient;

electrically coupling a ground electrode to an exterior of the patient; and

delivering an electric field between the monopolar electrode and the ground electrode to reduce neural communication along the post-ganglionic nerve,

wherein delivering the electric field results in a therapeutically beneficial reduction in blood pressure of the patient.

2. The method of claim 1 , wherein delivering the electric field further comprises delivering a pulsed electric field.

3. The method of claim 1 , wherein reducing neural communication along the post-ganglionic nerve further comprises at least partially denervating the kidney.

4. The method of claim 1 , wherein reducing neural communication along the post-ganglionic nerve further comprises inducing an effect in the nerve chosen from the group consisting of irreversible electroporation, electrofusion, necrosis, apoptosis, gene expression alteration, cytokine up-regulation alteration, ablation, and combinations thereof.

5. The method of claim 1 , wherein reducing neural communication along the post-ganglionic nerve further comprises thermally modulating the function of the nerve.

6. The method of claim 1 , wherein reducing neural communication along the post-ganglionic nerve further comprises, on average during delivery of the electric field, modulating the function of the nerve substantially athermally.

7. The method of claim 1 , wherein placing the monopolar electrode in proximity to the post-ganglionic nerve further comprises placing the electrode at a position chosen from the group consisting of within renal vasculature, external to renal vasculature, external to renal vasculature via a laparoscopic approach, external to renal vasculature via an intra-to-extravascular approach and combinations thereof.

8. The method of claim 1 , wherein electrically coupling the ground electrode to the exterior of the patient further comprises attaching a ground pad to skin of the patient.

9. The method of claim 1 , wherein placing a monopolar electrode in proximity to a post-ganglionic nerve that innervates the kidney further comprises positioning the electrode within a renal vasculature of the patient.

10. The method of claim 9 , wherein positioning the electrode within the renal vasculature of the patient further comprises contacting the electrode with a vessel wall of the renal vasculature of the patient.

11. The method of claim 1 , wherein reducing neural communication along the post-ganglionic nerve further comprises at least partially ablating the nerve.

12. The method of claim 1 , further comprising monitoring tissue impedance with the monopolar electrode.

13. The method of claim 1 , further comprising monitoring temperature via the monopolar electrode.

14. The method of claim 1 wherein reducing neural communication along the post-ganglionic nerve comprises reducing afferent neural activity across the nerve.

15. The method of claim 1 wherein reducing neural communication along the post-ganglionic nerve comprises reducing efferent neural activity across the nerve.

16. A method for treating hypertension in a human patient via renal denervation, the method comprising:

placing a monopolar electrode at least substantially proximate to a post-ganglionic nerve that innervates a kidney of a patient;

electrically coupling a ground electrode to an exterior of the patient; and

delivering an electric field between the monopolar electrode and the ground electrode such that the resulting electric field attenuates neural communication along the post-ganglionic nerve,

wherein delivering the electric field results in a therapeutically beneficial reduction in blood pressure of the patient.

17. The method of claim 16 wherein:

delivering the electric field further comprises delivering a pulsed electric field; and

heating the post-ganglionic nerve further comprises at least partially denervating the kidney.

18. The method of claim 16 wherein placing the monopolar electrode further comprises positioning the electrode at a location chosen from the group consisting of within the renal vasculature, external to the renal vasculature, through a vessel wall of the renal vasculature, and combinations thereof.

19. A method for at least partially denervating a kidney of a human patient, the method comprising:

placing a monopolar electrode in proximity to a post-ganglionic nerve that innervates the kidney;

electrically coupling a ground electrode to an exterior of the patient; and

delivering an electric field between the monopolar electrode and the ground electrode to at least partially denervate the kidney,

wherein at least partially denervating the kidney results in a therapeutically beneficial reduction in blood pressure of the patient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2023
From: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 064315/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 030285/0723 →
CHANGE OF NAME Recorded Apr 25, 2013
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 030293/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2006
From: DEMARAIS, DENISE; GIFFORD III, HANSON; DEEM, MARK; LEVIN, HOWARD R.; GELFAND, MARK; ZADNO, NICOLAS
To: ARDIAN, INC.
Reel/Frame 018113/0063 →
Continuity (11)
Continuation In Part 11129765 · May 13, 2005
Continuation In Part 10408665 · Apr 8, 2003
Continuation In Part 11189563 · Jul 25, 2005
Continuation In Part 11266933 · Nov 4, 2005
Continuation In Part 11363867 · Feb 27, 2006
Provisional Application 60616254 · Oct 5, 2004
Provisional Application 60624793 · Nov 2, 2004
Provisional Application 60442970 · Jan 29, 2003
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60370190 · Apr 8, 2002
Related Publication 20060265015A1 · Nov 23, 2006